Navigation Links
Researchers Identify Intracellular Pathway of Alfacell's Onconase

Paper Published in Journal of Cell Science Shows ONCONASE Uptake in Cells Differs from other RNases

BLOOMFIELD, N.J., April 05, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that European researchers have identified the pathway that ONCONASE (ranpirnase) follows to enter cells.

Published in the Journal of Cell Science (2007; 120: 1405-1411), a paper based on studies conducted at the University of Girona in Spain and the University of Montpellier II in France shows that ONCONASE enters cells using AP-2/clathrin-mediated endocytosis, enabling its subsequent delivery to the cytosol. The published data indicate that unlike other RNases, the ONCONASE endocytosis pathway is not targeted to lysosomes.

"ONCONASE has a very specific property in that it is selectively toxic to malignant cells," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "The Journal of Cell Science paper is another reflection of the strong interest that the scientific and medical communities have in understanding ONCONASE's performance. Ongoing independent research like this at leading institutions is providing us with further data that is useful in our efforts to expand the potential therapeutic opportunities for our technology platform."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCO NASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com .

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact

    David Schull or Wendy Lau

    Noonan Russo

    212-845-4271

    

    


    Investor Contact:

    Andreas Marathovouniotis

    Noonan Russo

    212-845-4253

    

david.schull@eurorscg.com wendy.lau1@eurorscg.com andreas.marathis@eurorscg.com

CONTACT: David Schull or Wendy Lau, both of Noonan Russo, +1-212-845-4271, or ; or AndreasMarathovouniotis, of Noonan Russo, +1-212-845-4253,; all for Alfacell Corporation david.schull@eurorscg.com wendy.lau1@eurorscg.com andreas.marathis@eurorscg.com

Web site: http://www.alfacell.com/

Ticker Symbol: (NASDAQ-NMS:ACEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Researchers Discover Method for Identifying How Cancer Evades the Immune System
4. Researchers Discover Gene For Rare Skin Disorder
5. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
6. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
9. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
10. Researchers Urge Caution in Using ESAs for Cancer-Related Anemia
11. Researchers Identify New Genetic Risk Factors for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Medical information ... to increase their self-service capabilities to manage inquiries ... (HCPs). New research from consulting leader ... have developed self-service website portals where HCPs can ... just one of many findings to emerge from ...
(Date:2/24/2017)... 2017 The U.S. Food and Drug ... Kit, performed on the Pheno System. This is ... bloodstream infections and provide information about which antibiotics ... sensitivity). The test also reduces the amount of ... which can guide antibiotic treatment recommendations more quickly. ...
(Date:2/24/2017)... 2017 ITL Limited, ( ASX: ITD ... erfreut, für das zum 31. Dezember 2016 endende ... Ergebnisse vorlegen zu können. Eine vollständige Präsentation „Ergebnisse ... finden Sie hier . Glanzpunkte ... (Dez. 2015: 1,04 Millionen USD; +104 %) Gewinn ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... VA (PRWEB) , ... February 24, 2017 , ... The ... winners for excellence in radiology marketing programs at the annual Building Better Radiology ... Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given out ...
(Date:2/24/2017)... MI (PRWEB) , ... February 24, 2017 , ... ... in Charlevoix, once again hosted their Military Wedding Giveaway, with the winning ... hosted by Castle Farms with services generously donated from local vendors: A Matter ...
(Date:2/23/2017)... Boulder, CO (PRWEB) , ... February 23, 2017 , ... ... to announce the winner of the 2016 National Education Policy Center Bunkum Award. We ... report reviewed in 2016. , This year’s Bunkum winner is the Center for American ...
(Date:2/23/2017)... ... , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS ... longtime supporter of the event. , "We are pleased that KLS Martin is joining ... 2017 ACPA President. "KLS Martin has a long track record of support of the ...
Breaking Medicine News(10 mins):